Zantac Cancer Risk Suspected After Known Carcinogen Found By FDA
Following an alarming discovery announced by the FDA today, the lawyers at Saiontz & Kirk, P.A., are evaluating the potential for Zantac lawsuits, since the known human carcinogen N-nitrosodimethylamine (NDMA) has been found in the widely used heartburn drug.
Our law firm currently represents individuals nationwide who are pursuing valsartan lawsuits after developing cancer following exposure to this same chemical, which was found throughout much of the U.S. supply of that blood pressure drug last year.
While this new information about the Zantac cancer risk is being closely reviewed and analyzed, our law firm is evaluating whether financial compensation may be available for individuals who may have developed several types of cancer linked to NDMA exposure, which could be a side effect of Zantac contamination, including:
- Prostate Cancer
- Pancreatic Cancer
- Esophageal Cancer
- Stomach Cancer
- Breast Cancer
- Liver Cancer
- Bladder Cancer
- Colorectal Cancer
- Kidney Cancer
- Lung Cancer
To submit information about a potential claim for yourself or a loved one, request a free consultation and case evaluation. There are no fees or expenses unless our lawyers determine we are able to move forward with this case and obtain a Zantac settlement or recovery for you or your family.
Zantac Cancer Warning
This investigation was launched after the FDA issued a warning today, indicating that there is now evidence Zantac may contain cancer-causing impurities. The statement indicates that levels of N-nitrosodimethylamine (NDMA) were detected from laboratory tests of certain versions of the drug.
Zantac (ranitidine) belongs to a class of older heartburn drugs, known as H2 receptor antagonists, which also includes Pepcid AC and Tagamet. It is used to treat gastroesophageal reflux disease (GERD), heartburn with acid indigestion and stomach ulcers.
As of September 13, 2019, the FDA indicates that the investigation remains in its early stages. While preliminary reports indicate the levels of NDMA were low in the first samples detected, it is unclear how widespread the problem is, and how long users were exposed to contaminated Zantac pills, which may greatly impact the cancer risk.
In previous NDMA reports, which resulted in numerous recalls for valsartan, irbesartan, losartan and similar blood pressure medications earlier this year, the levels of the contaminant varied widely from one batch of the active ingredient to another.
The Zantac problems were first detected by an online pharmacy.
Zantac Case Evaluations Provided
As part of our evaluation of the potential for Zantac cancer lawsuits, submit information if you or a loved one were diagnosed following long-term use of the medication. All claims are being investigated on a contingency fee basis, which means that there are never any out-of-pocket expenses or fees unless our lawyers are able to successfully obtain a recovery in your case.